دورية أكاديمية
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
| العنوان: | Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST. |
|---|---|
| المؤلفون: | de Mestier L; Department of Pancreatology and Digestive Oncology, Université Paris-Cité, INSERM U1149, Beaujon University Hospital, Clichy, France., Resche-Rigon M; Department of Epidemiology and Biostatistics, Université Paris-Cité, Saint-Louis Hospital, Paris, France., Dromain C; Department of Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Lamarca A; Department of Medical Oncology, The Christie Hospital, Manchester, UK., La Salvia A; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., de Baker L; Department of Radiology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium., Fehrenbach U; Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Pusceddu S; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Colao A; Endocrinology Unit, Department of Clinical Medicine and Surgery, Università Federico II di Napoli, Naples, Italy.; Endocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, ENETS Center of Excellence, Rome, Italy., Borbath I; Department of Hepatology and Gastroenterology, University Hospital St Luc/UCLouvain, Woluwe, Belgium., de Haas R; Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Rinzivillo M; Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy., Zerbi A; Pancreatic Surgery, Humanitas Clinical and Research Center, Rozzano-, Milano, Italy., Funicelli L; Division of Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy., de Herder WW; Department of Internal Medicine, Erasmus MC and Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Selberherr A; Division of General Surgery, Department of Surgery, Medical University, Vienna, Austria.; Department of General and Visceral Surgery, Evangelisches Krankenhaus Wien, Vienna, Austria., Wagner AD; Department of Medical Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Manoharan P; Department of Radiology and Nuclear Medicine, The Christie, Manchester, UK., De Cima A; Department of Radiology, Hospital Universitario 12 de Octubre, Madrid, Spain., Lybaert W; Department of Medical Oncology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium., Jann H; Department of Hepatology and Gastroenterology, Charité-University, Charité-Universitätsmedizin, Berlin, Germany., Prinzi N; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Faggiano A; Endocrinology Unit, Department of Clinical Medicine and Surgery, Università Federico II di Napoli, Naples, Italy., Annet L; Department of Radiology, Cliniques Universitaires Saint-Luc/UCLouvain, Brussels, Belgium., Walenkamp A; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Panzuto F; Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy.; Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, ENETS Center of Excellence, Rome, Italy., Pedicini V; Department of Radiology, Humanitas Clinical and Research Center, Rozzano-Milano, Italy., Pitoni MG; Post-graduate School in Radiodiagnostics, University of Milan, Milan, Italy., Siebenhuener A; Department of Gastroenterology and Hepatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland., Mayerhoefer ME; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Ruszniewski P; Department of Pancreatology and Digestive Oncology, Université Paris-Cité, INSERM U1149, Beaujon University Hospital, Clichy, France., Vullierme MP; Department of Radiology, Université Paris-Cité, Beaujon Hospital, Clichy, France. |
| المصدر: | Journal of neuroendocrinology [J Neuroendocrinol] 2023 Jun; Vol. 35 (6), pp. e13311. Date of Electronic Publication: 2023 Jun 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley & Sons Country of Publication: United States NLM ID: 8913461 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2826 (Electronic) Linking ISSN: 09538194 NLM ISO Abbreviation: J Neuroendocrinol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2010->: Malden, MA : Wiley & Sons Original Publication: Eynsham, Oxon, UK : Oxford University Press, c1989- |
| مواضيع طبية MeSH: | Neuroendocrine Tumors*/diagnostic imaging , Neuroendocrine Tumors*/drug therapy , Liver Neoplasms*/diagnostic imaging , Liver Neoplasms*/drug therapy, Humans ; Response Evaluation Criteria in Solid Tumors ; Retrospective Studies ; Tomography, X-Ray Computed |
| مستخلص: | RECIST 1.1 criteria are commonly used with computed tomography (CT) to evaluate the efficacy of systemic treatments in patients with neuroendocrine tumors (NETs) and liver metastases (LMs), but their relevance is questioned in this setting. We aimed to explore alternative criteria using different numbers of measured LMs and thresholds of size and density variation. We retrospectively studied patients with advanced pancreatic or small intestine NETs with LMs, treated with systemic treatment in the first-and/or second-line, without early progression, in 14 European expert centers. We compared time to treatment failure (TTF) between responders and non-responders according to various criteria defined by 0%, 10%, 20% or 30% decrease in the sum of LM size, and/or by 10%, 15% or 20% decrease in LM density, measured on two, three or five LMs, on baseline (≤1 month before treatment initiation) and first revaluation (≤6 months) contrast-enhanced CT scans. Multivariable Cox proportional hazard models were performed to adjust the association between response criteria and TTF on prognostic factors. We included 129 systemic treatments (long-acting somatostatin analogs 41.9%, chemotherapy 26.4%, targeted therapies 31.8%), administered as first-line (53.5%) or second-line therapies (46.5%) in 91 patients. A decrease ≥10% in the size of three LMs was the response criterion that best predicted prolonged TTF, with significance at multivariable analysis (HR 1.90; 95% CI: 1.06-3.40; p = .03). Conversely, response defined by RECIST 1.1 did not predict prolonged TTF (p = .91), and neither did criteria based on changes in LM density. A ≥10% decrease in size of three LMs could be a more clinically relevant criterion than the current 30% threshold utilized by RECIST 1.1 for the evaluation of treatment efficacy in patients with advanced NETs. Its implementation in clinical trials is mandatory for prospective validation. Criteria based on changes in LM density were not predictive of treatment efficacy. CLINICAL TRIAL REGISTRATION: Registered at CNIL-CERB, Assistance publique hopitaux de Paris as "E-NETNET-L-E-CT" July 2018. No number was assigned. Approved by the Medical Ethics Review Board of University Medical Center Groningen. (© 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.) |
| References: | Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335-1342. doi:10.1001/jamaoncol.2017.0589. Borbath I, Garcia-Carbonero R, Bikmukhametov D, et al. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. Eur J Cancer. 2022;168:80-90. doi:10.1016/j.ejca.2022.03.007. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844-860. doi:10.1016/j.annonc.2020.03.304. de Mestier L, Lepage C, Baudin E, et al. Digestive neuroendocrine neoplasms (NEN): French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2020;52:473-492. doi:10.1016/j.dld.2020.02.011. Rinke A, Müller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. JCO. 2009;27:4656-4663. doi:10.1200/JCO.2009.22.8510. Caplin ME, Pavel M, Cwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224-233. doi:10.1056/NEJMoa1316158. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968-977. doi:10.1016/S0140-6736(15)00817-X. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523. doi:10.1056/NEJMoa1009290. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513. doi:10.1056/NEJMoa1003825. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125-135. doi:10.1056/NEJMoa1607427. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-523. doi:10.1056/NEJM199202203260804. Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36:abstract 4004. doi:10.1200/JCO.2018.36.15_suppl.4004. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247. doi:10.1016/j.ejca.2008.10.026. Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology. 2017;105:212-244. doi:10.1159/000471879. de Mestier L, Dromain C, d'Assignies G, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer. 2014;21:R105-R120. doi:10.1530/ERC-13-0365. Merino-Casabiel X, Aller J, Arbizu J, et al. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol. 2018;20:1522-1528. doi:10.1007/s12094-018-1881-9. Thiis-Evensen E, Poole AC, Nguyen H-TT, Sponheim J. Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease. BMC Cancer. 2020;20:466. doi:10.1186/s12885-020-06963-6. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-1759. doi:10.1200/JCO.2006.07.3049. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60. doi:10.1055/s-0030-1247132. WHO Classification of Tumours. Digestive System Tumours. Vol. 1. 5th ed. IARC; 2019. Perren A, Couvelard A, Scoazec J-Y, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105:196-200. doi:10.1159/000457956. Zappa M, Hentic O, Vullierme M-P, et al. Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible? Endocr Connect. 2017;6:33-38. doi:10.1530/EC-16-0092. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. Capdevila J, Grande E, García-Carbonero R, et al. Position statement on the diagnosis, treatment, and response evaluation to systemic therapies of advanced neuroendocrine tumors, with a special focus on radioligand therapy. Oncologist. 2022;27:e328-e339. doi:10.1093/oncolo/oyab041. Lamarca A, Barriuso J, Kulke M, et al. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. Br J Cancer. 2018;118:181-188. doi:10.1038/bjc.2017.402. Lamarca A, Ronot M, Moalla S, et al. Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: the GREPONET-2 study. Clin Cancer Res. 2019;25:6692-6699. doi:10.1158/1078-0432.CCR-19-0963. Faivre S, Ronot M, Dreyer C, et al. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Target Oncol. 2012;7:127-133. doi:10.1007/s11523-012-0216-y. Luo Y, Chen J, Huang K, et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi criteria? BMC Cancer. 2017;17:154. doi:10.1186/s12885-017-3150-7. Solis-Hernandez MP, Fernandez del Valle A, Carmona-Bayonas A, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br J Cancer. 2019;121:537-544. doi:10.1038/s41416-019-0558-7. Moalla S, Arfi Rouche J, Foulon S, et al. Are we reproducible in measurement of NET liver metastasis? Dig Liver Dis. 2017;49:1121-1127. doi:10.1016/j.dld.2017.05.015. |
| فهرسة مساهمة: | Keywords: computed tomography; neuroendocrine tumors; response evaluation; systemic treatments |
| SCR Disease Name: | Gastro-enteropancreatic neuroendocrine tumor |
| تواريخ الأحداث: | Date Created: 20230622 Date Completed: 20230703 Latest Revision: 20240118 |
| رمز التحديث: | 20240118 |
| DOI: | 10.1111/jne.13311 |
| PMID: | 37345276 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2826 |
|---|---|
| DOI: | 10.1111/jne.13311 |